Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05249634 · ClinicalTrials.gov registry record · Phase 2
Testosterone Treatment in Men with Chronic Kidney Disease
A Phase 2 study of Hypogonadism, Male and Kidney Disease, Chronic, sponsored by St. Louis University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05249634: Recruiting Phase 2 study of Hypogonadism, Male and Kidney Disease, Chronic, sponsored by St. Louis University.
NCT05249634 is a Phase 2 study of Hypogonadism, Male and Kidney Disease, Chronic that is actively recruiting participants, run by St. Louis University. The registered enrollment target is 20 participants, below the 111-participant average among 12 other Hypogonadism, Male trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05249634, a Phase 2 study of Hypogonadism, Male and Kidney Disease, Chronic, is actively recruiting participants, sponsored by St. Louis University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This study in being conducted in men who have low testosterone and chronic kidney disease. The investigators will evaluate the effects of an oral testosterone preparation, JATENZO, on testosterone levels and hemoglobin (red blood cells).
Primary Outcome
Testosterone concentrations in serum measured multiple times during the study
Conditions Studied
Interventions
- DRUG Jatenzo Pill
Study Locations (1)
Missouri
- Saint Louis Univeristy - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-03-15 |
| Est. Completion | 2028-12 |
| Phase | Phase 2 |
What NCT05249634 shows while recruiting
NCT05249634 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 111-participant average among 12 other Hypogonadism, Male trials with a reported enrollment target (82% lower).
The record links to 2 conditions, with Hypogonadism, Male appearing as the primary indexed condition, and to 1 intervention - of which Jatenzo Pill is the first listed.
NCT05249634 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT05249634 about?
NCT05249634 is a clinical study titled "Testosterone Treatment in Men with Chronic Kidney Disease". This study in being conducted in men who have low testosterone and chronic kidney disease. The investigators will evaluate the effects of an oral testosterone preparation, JATENZO, on testosterone levels and hemoglobin (red blood cells).
What is the current status of trial NCT05249634?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2022-03-15. Estimated completion is 2028-12.
What conditions does trial NCT05249634 study?
This clinical trial studies the following conditions: Hypogonadism, Male, Kidney Disease, Chronic.
What interventions are being tested in trial NCT05249634?
The interventions under investigation include: Jatenzo Pill (DRUG).
Who is sponsoring clinical trial NCT05249634?
This trial is sponsored by St. Louis University, which has 107 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05249634 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypogonadism, Male
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05249634's enrollment target sits among peer trials
20 12th of 12 higher than 1 of 12 other Hypogonadism, Male trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypogonadism, Male trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism
RECRUITING · Phase 2
-
Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
RECRUITING · Phase 2
-
Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone
RECRUITING · Phase 2
-
Clomid in Men With Low Testosterone With and Without Prior Treatment
COMPLETED · Phase 2
-
28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men
COMPLETED · Phase 2
-
52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI